SI2200431T1 - Sestave in metode za zdravljenje raka - Google Patents

Sestave in metode za zdravljenje raka

Info

Publication number
SI2200431T1
SI2200431T1 SI200831655A SI200831655A SI2200431T1 SI 2200431 T1 SI2200431 T1 SI 2200431T1 SI 200831655 A SI200831655 A SI 200831655A SI 200831655 A SI200831655 A SI 200831655A SI 2200431 T1 SI2200431 T1 SI 2200431T1
Authority
SI
Slovenia
Prior art keywords
methods
cancer treatment
novel compositions
compositions
novel
Prior art date
Application number
SI200831655A
Other languages
English (en)
Inventor
Chiang Jia Li
Keith Mikule
Youzhi Li
Original Assignee
Boston Biomedical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical, Inc. filed Critical Boston Biomedical, Inc.
Publication of SI2200431T1 publication Critical patent/SI2200431T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
SI200831655A 2007-09-10 2008-09-10 Sestave in metode za zdravljenje raka SI2200431T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97114407P 2007-09-10 2007-09-10
US1337207P 2007-12-13 2007-12-13
EP08830633.7A EP2200431B1 (en) 2007-09-10 2008-09-10 Novel compositions and methods for cancer treatment
PCT/US2008/075906 WO2009036101A1 (en) 2007-09-10 2008-09-10 Novel compositions and methods for cancer treatment

Publications (1)

Publication Number Publication Date
SI2200431T1 true SI2200431T1 (sl) 2016-10-28

Family

ID=40452461

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200831626A SI2194987T1 (sl) 2007-09-10 2008-09-10 Novi inhibitorji poti stat3 in inhibitorji matičnih celic raka
SI200831606A SI2190429T1 (sl) 2007-09-10 2008-09-10 Nova skupina inhibitorjev poti stat3 in inhibitorjev poti matičnih celic raka
SI200831655A SI2200431T1 (sl) 2007-09-10 2008-09-10 Sestave in metode za zdravljenje raka

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200831626A SI2194987T1 (sl) 2007-09-10 2008-09-10 Novi inhibitorji poti stat3 in inhibitorji matičnih celic raka
SI200831606A SI2190429T1 (sl) 2007-09-10 2008-09-10 Nova skupina inhibitorjev poti stat3 in inhibitorjev poti matičnih celic raka

Country Status (15)

Country Link
US (12) US9745278B2 (sl)
EP (6) EP2190429B1 (sl)
JP (16) JP5701603B2 (sl)
CN (6) CN105963289B (sl)
CA (4) CA2736564A1 (sl)
CY (3) CY1117604T1 (sl)
DK (4) DK3050566T3 (sl)
ES (3) ES2584904T3 (sl)
HK (3) HK1148906A1 (sl)
HR (3) HRP20160430T1 (sl)
HU (3) HUE029111T2 (sl)
PL (4) PL2194987T3 (sl)
PT (2) PT2194987T (sl)
SI (3) SI2194987T1 (sl)
WO (3) WO2009036099A1 (sl)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
KR20130088908A (ko) 2008-06-17 2013-08-08 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
UA103492C2 (ru) 2008-07-08 2013-10-25 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
HUE032958T2 (hu) 2008-08-04 2017-11-28 Wyeth Llc 4-Anilino-3-ciano-kinolinok és capecitabin antineoplasztikus kombinációi
AU2009322625A1 (en) * 2008-12-01 2011-07-21 University Of Central Florida Research Foundation, Inc. Drug composition cytotoxic for pancreatic cancer cells
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
CN101897979B (zh) * 2009-05-27 2012-08-22 上海市计划生育科学研究所 治疗***疾病的靶向药物
US20130129675A1 (en) * 2009-12-04 2013-05-23 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
KR101778320B1 (ko) * 2009-12-28 2017-09-13 잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 1,3,4-옥사디아졸-2-카르복사미드 화합물
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
CA2787673A1 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
CN106860443A (zh) * 2010-03-19 2017-06-20 北京强新生物科技有限公司 靶向癌症干细胞的新的化合物和组合物
BR112012023661A2 (pt) * 2010-03-19 2020-11-24 Boston Biomedical, Inc. novos compostos e novas composições direcionadas a células-tronco cancerosas
CA2793527A1 (en) * 2010-03-19 2011-09-22 Boston Biomedical, Inc. Use of naphthofuran derivatives in the treatment of cancer
AU2015218436B9 (en) * 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
WO2011130677A1 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of cancer stem cells
US20110301194A1 (en) * 2010-06-02 2011-12-08 Arqule, Inc. Method for Determining Treatment Efficacy
WO2012024818A1 (en) * 2010-08-24 2012-03-01 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Novel anphthoquinones for disease therapies
US20130236473A1 (en) * 2010-09-16 2013-09-12 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
EP2643001A4 (en) * 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd METHOD OF TREATING CANCER
WO2012071648A1 (en) * 2010-11-30 2012-06-07 London Health Sciences Centre Research Inc. Egfr antagonist for the treatment of heart disease
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
CA2837560C (en) * 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
SG11201400526TA (en) * 2011-09-12 2014-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
CA2855368A1 (en) * 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CN104080449A (zh) * 2012-02-17 2014-10-01 舟山海中洲新生药业有限公司 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
CN104797267A (zh) 2012-06-26 2015-07-22 德玛医药 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法
CN106421795A (zh) * 2012-10-08 2017-02-22 贾力 预防原发性肿瘤在手术切除后再转移的药用组合物
DE102013003107A1 (de) 2013-02-25 2014-09-11 Thomas Rühl Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
CN106211758B (zh) * 2013-04-09 2021-03-23 北京强新生物科技有限公司 2-乙酰基萘并[2,3-b]呋喃-4,9-二酮用于治疗癌症的用途
US10745489B2 (en) 2013-04-29 2020-08-18 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
EP2992018B1 (en) * 2013-04-29 2019-02-13 OGD2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
TWI657085B (zh) 2013-10-04 2019-04-21 英菲尼提製藥股份有限公司 雜環化合物及其用途
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3099297A4 (en) * 2014-01-27 2017-06-07 Boston Biomedical, Inc. Novel methods for treating cancer
WO2015120304A1 (en) * 2014-02-07 2015-08-13 Boston Biomedical, Inc. 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
US11406707B2 (en) 2014-02-10 2022-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 phosphorylation during graft-versus-host disease
ES2913486T3 (es) 2014-03-19 2022-06-02 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para la utilización en el tratamiento de trastornos mediados por PI3K-gamma
JP6894236B2 (ja) * 2014-03-26 2021-06-30 デノボ バイオファーマ エルエルシー 免疫刺激活性を有するレトロウイルスベクター
WO2015164870A1 (en) 2014-04-25 2015-10-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gamma-aa-peptide stat3/dna inhibitors and methods of use
US20170266182A1 (en) * 2014-05-09 2017-09-21 The Brigham And Women's Hospital, Inc. Treatment of IgG-Immune Complex-Mediated Organ Damage
AU2015272560B2 (en) * 2014-06-09 2019-02-14 Kyoto Pharmaceutical Industries, Ltd. Novel anticancer agent
CA2955177A1 (en) * 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
US10906914B2 (en) 2015-01-08 2021-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furoquinolinediones as inhibitors of TDP2
JP6630364B2 (ja) 2015-03-27 2020-01-15 ボストン バイオメディカル， インコーポレイテッド 水溶性プロドラッグ
CN104693279A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 关于信号传导及转录激活因子抑制多肽及其应用
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
MX2017013358A (es) * 2015-04-17 2018-08-01 Boston Biomedical Inc Métodos para tratar el cáncer.
BR112017022281A2 (pt) * 2015-04-17 2018-07-10 Boston Biomedical Inc métodos para tratar câncer
AU2016249157A1 (en) * 2015-04-17 2017-11-02 Boston Biomedical, Inc. Methods for treating cancer
US20180250261A1 (en) * 2015-04-27 2018-09-06 Boston Biomedical, Inc. Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
CN115837028A (zh) 2015-05-14 2023-03-24 努卡那有限公司 癌症治疗
EP3294299A1 (en) * 2015-05-15 2018-03-21 Novartis AG Methods for treating egfr mutant cancers
US20180140572A1 (en) * 2015-06-03 2018-05-24 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
WO2017013865A1 (ja) * 2015-07-17 2017-01-26 大日本住友製薬株式会社 ２－アセチル－４Ｈ，９Ｈ－ナフト［２，３－ｂ］フラン－４，９－ジオンの製造方法
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017023866A1 (en) * 2015-07-31 2017-02-09 Boston Biomedical, Inc. Method of targeting stat3 and other non-druggable proteins
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
JP7038653B2 (ja) 2015-10-05 2022-03-18 ニューカナ パブリック リミテッド カンパニー 併用療法
US20190017054A1 (en) * 2016-01-07 2019-01-17 Luni Emdad Method of modulating survival and stemness of cancer stem cells by mda-9/syntenin (sdcbp)
CA3011800A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CN109104862A (zh) * 2016-03-01 2018-12-28 中央研究院 4,9-二氧代-4,9-二氢萘并[2,3-b]呋喃-3-羧酰胺衍生物及其用于治疗增生性疾病与感染性疾病的用途
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
JP2017171640A (ja) * 2016-03-25 2017-09-28 学校法人兵庫医科大学 癌の治療システム
US10738023B2 (en) 2016-03-25 2020-08-11 Sumitomo Dainippon Pharma Co., Ltd. Method for producing 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, and said related substance
CN105906595A (zh) * 2016-04-23 2016-08-31 陈斌 丙酸倍氯米松的药物组合物及其在生物医药中的应用
CN105837541A (zh) * 2016-04-23 2016-08-10 何淑琼 磷酸苯丙哌林的药物组合物及其在生物医药中的应用
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018005444A2 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CN106380456B (zh) * 2016-08-29 2019-03-26 中南大学 一种合成苯并呋喃萘醌衍生物的方法
US20190375723A1 (en) 2016-11-22 2019-12-12 Boston Biomedical, Inc. New Naphtho[2,3-B]Furan Derivatives
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
AU2017368135A1 (en) * 2016-11-30 2019-06-13 Tyme, Inc. Tyrosine derivatives and compositions comprising them
TW201827050A (zh) * 2017-01-22 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｅｇｆｒ／ｈｅｒ２抑制劑聯合嘧啶類抗代謝藥物的用途
WO2018183908A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
JP2020525758A (ja) * 2017-06-04 2020-08-27 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズＲａｐｐａｐｏｒｔ Ｆａｍｉｌｙ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｒｅｓｅａｒｃｈ ｉｎ ｔｈｅ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅｓ 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット
CN111132614A (zh) * 2017-07-20 2020-05-08 路易斯安娜州立大学监测委员会，农业和机械学院 使用脉冲磁场梯度对恶性癌细胞的靶向渗透裂解
CA3074981A1 (en) 2017-09-22 2019-03-28 Sumitomo Dainippon Pharma Co., Ltd. Chemically activated water-soluble prodrug
EP3710050A4 (en) * 2017-11-16 2021-06-16 TyrNovo Ltd. COMBINATIONS OF IRS / STAT3 DOUBLE MODULATORS AND ANTI-PD-1 / PD-L1 AMBODIES FOR TREATMENT OF CANCER
EP3501511A1 (en) * 2017-12-22 2019-06-26 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Means for preventing and treating brain metastasis
WO2019131940A1 (ja) * 2017-12-28 2019-07-04 株式会社カネカ 多能性幹細胞凝集抑制剤
CN107973788B (zh) * 2018-01-09 2021-07-09 沈阳药科大学 Bbi608衍生物及其制备与用途
ES2941771T3 (es) 2018-03-20 2023-05-25 Sumitomo Pharma Co Ltd Derivados de dihidrocromeno
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
WO2019232214A1 (en) 2018-05-31 2019-12-05 Boston Biomedical, Inc. Methods of using napabucasin
CN112703001A (zh) * 2018-09-18 2021-04-23 株式会社益力多本社 使用喹啉羧酰胺衍生物的癌症联用疗法
JP2022504760A (ja) * 2018-10-12 2022-01-13 １グローブ バイオメディカル カンパニー， リミテッド 化学療法難治性がんの治療のための新しい併用薬方法
CN109288847A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物
CN109223758A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴类stat3抑制剂联合用药物组合物
CN109200044A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物
CN109331004A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物
CN109200052A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物
CN109288845A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法
CN109846888A (zh) * 2018-10-31 2019-06-07 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物
CN109288846A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物
CN109966297A (zh) * 2018-10-31 2019-07-05 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物
CN109172563A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
US20220211708A1 (en) * 2019-04-09 2022-07-07 Generos Biopharma Ltd. Pharmaceutical combination of pimozide and methotrexate and use thereof
US11564913B2 (en) * 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer
CN110218198B (zh) * 2019-05-22 2022-06-28 广州中医药大学(广州中医药研究院) 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用
US20220315551A1 (en) * 2019-06-14 2022-10-06 Sumitomo Dainippon Pharma Co., Ltd. 2-ALKYLCARBONYL[2,3-b]FURAN-4,9-DIONE PRODUCTION METHOD AND PRODUCTION INTERMEDIATE THEREFOR
JP7287929B2 (ja) * 2019-09-25 2023-06-06 住友ファーマ株式会社 ジヒドロクロメン誘導体を含有する医薬
WO2021101902A1 (en) * 2019-11-20 2021-05-27 Yale University Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
WO2021113761A1 (en) * 2019-12-05 2021-06-10 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases associated with fibrosis
CN115135326A (zh) * 2020-03-16 2022-09-30 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
EP4149667A1 (en) * 2020-05-11 2023-03-22 Purdue Research Foundation Scaled-up synthesis of lomustine under continuous flow conditions
CN114286684B (zh) * 2020-07-27 2024-01-05 华中科技大学 与stat3相关的疾病的预防和/或治疗
WO2022216930A1 (en) * 2021-04-08 2022-10-13 Virginia Commonwealth University Novel mda-9 antagonist with anti-metastatic potential
CN114591306B (zh) * 2022-03-03 2024-03-01 陕西中医药大学 一种1,2,4-***环的1,4萘醌类stat3抑制剂及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472133A (en) * 1947-03-20 1949-06-07 Du Pont Thiophanthraquinone derivatives
SU1049490A1 (ru) 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPS616149A (ja) 1984-06-20 1986-01-11 Mitsubishi Electric Corp 無機絶縁体の製法
JPS63196576A (ja) * 1987-02-10 1988-08-15 Tetsuo Ikegawa フラルナフトキノン誘導体と制癌剤及びその製造方法
EP0309926A3 (de) 1987-09-29 1990-12-05 Siemens Aktiengesellschaft Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik
JPH01121284A (ja) 1987-11-06 1989-05-12 Eisai Co Ltd トコフェロール　ｎ，ｎ−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JP2942015B2 (ja) * 1990-07-10 1999-08-30 キヤノン株式会社 電子写真感光体およびそれを用いた電子写真装置
DE69131033T2 (de) * 1990-07-10 1999-11-18 Canon Kk Lichtempfindliches elektrophotographisches Element
TW252136B (sl) 1992-10-08 1995-07-21 Ciba Geigy
JP3598168B2 (ja) 1996-03-18 2004-12-08 独立行政法人 科学技術振興機構 抗ウイルス剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
JPH1165141A (ja) * 1997-08-11 1999-03-05 Canon Inc 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
US6174913B1 (en) * 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
JP2003525862A (ja) 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
CA2366787C (en) * 1999-04-01 2013-03-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma
US6482943B1 (en) * 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
CA2386793C (en) 1999-08-02 2006-03-28 F. Hoffmann-La Roche Ag New selective retinoid agonists
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
AU2002307217A1 (en) * 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
KR20040096497A (ko) 2001-11-29 2004-11-16 테라코스, 인크. 체외 광분리반출법 및/또는 세포소멸성 세포를 사용한특정 대상체의 전처리 방법
WO2003075917A1 (en) * 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
EP1344533B1 (en) 2002-03-15 2006-08-23 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
WO2004024145A1 (en) 2002-09-10 2004-03-25 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20060142271A1 (en) 2002-09-17 2006-06-29 Klaus Muller Novel lapacho compounds and methods of use thereof
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2535584A1 (en) 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20050049207A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
KR101287905B1 (ko) 2003-12-02 2013-07-23 클리블랜드 클리닉 파운데이션 플라젤린을 이용한 방사선으로부터의 보호방법
US7745468B2 (en) * 2003-12-11 2010-06-29 Board of Regents, University of Texas Systems The Compounds for treatment of cell proliferative diseases
DE10359828A1 (de) * 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
EP1748772A2 (en) * 2004-04-09 2007-02-07 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
AU2005270102A1 (en) * 2004-07-02 2006-02-09 Icos Corporation Compounds useful for inhibiting Chk1
CA2575056A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
BRPI0517652A (pt) * 2004-11-08 2008-10-14 Baxter Healthcare Sa composições farmacêuticas nanoparticuladas de inibidores de tubulina, métodos para as suas preparações e respectivos usos
AU2005309019A1 (en) * 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
WO2006071812A2 (en) * 2004-12-23 2006-07-06 H. Lee Moffitt Cancer Center And Research Institute Platinum iv complex inhibitor
CN101511179A (zh) * 2005-02-25 2009-08-19 密执安州立大学董事会 Stat3的小分子抑制剂及其用途
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2006126505A1 (ja) 2005-05-26 2006-11-30 The University Of Tokyo Stat機能阻害剤およびその応用
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
AU2006300877A1 (en) 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pSTAT3/IL-6 inhibitors
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2007145680A (ja) 2005-11-30 2007-06-14 Idemitsu Kosan Co Ltd 水素発生材料および水素発生方法
JP2009521423A (ja) * 2005-12-24 2009-06-04 バイオチカ テクノロジー リミテッド 抗癌剤として有用な２１−デオキシマクベシン類似体
WO2007087129A2 (en) * 2006-01-12 2007-08-02 Merck & Co., Inc. Fluorinated arylamide derivatives
JP5528708B2 (ja) * 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
WO2007100640A2 (en) * 2006-02-21 2007-09-07 The Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
CA2643562A1 (en) * 2006-02-24 2007-08-30 Anh Chau 2-(phenyl or heterocyclic)-1h-phenanthro[9,10-d]imidazoles
US8779151B2 (en) 2006-03-31 2014-07-15 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US8828451B2 (en) * 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
WO2008077062A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
JP4077863B1 (ja) * 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US20100298402A1 (en) 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
AU2015218436B9 (en) 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
CN106860443A (zh) 2010-03-19 2017-06-20 北京强新生物科技有限公司 靶向癌症干细胞的新的化合物和组合物
BR112012023661A2 (pt) 2010-03-19 2020-11-24 Boston Biomedical, Inc. novos compostos e novas composições direcionadas a células-tronco cancerosas
CA2793527A1 (en) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Use of naphthofuran derivatives in the treatment of cancer
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
CN106211758B (zh) 2013-04-09 2021-03-23 北京强新生物科技有限公司 2-乙酰基萘并[2,3-b]呋喃-4,9-二酮用于治疗癌症的用途
MX2017013358A (es) 2015-04-17 2018-08-01 Boston Biomedical Inc Métodos para tratar el cáncer.
BR112017022281A2 (pt) 2015-04-17 2018-07-10 Boston Biomedical Inc métodos para tratar câncer
AU2016249157A1 (en) 2015-04-17 2017-11-02 Boston Biomedical, Inc. Methods for treating cancer
US20180250261A1 (en) 2015-04-27 2018-09-06 Boston Biomedical, Inc. Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
US20180140572A1 (en) 2015-06-03 2018-05-24 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
CA3011800A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
JP2014221843A (ja) 2014-11-27
JP2016034976A (ja) 2016-03-17
CA2911990A1 (en) 2009-03-19
CY1118476T1 (el) 2017-07-12
EP3058941B1 (en) 2019-05-22
HUE029111T2 (en) 2017-02-28
ES2569215T3 (es) 2016-05-09
HRP20160625T1 (hr) 2016-08-12
JP2015034179A (ja) 2015-02-19
US20180030021A1 (en) 2018-02-01
JP2018131464A (ja) 2018-08-23
EP3050566A2 (en) 2016-08-03
JP2010539098A (ja) 2010-12-16
US20210115006A1 (en) 2021-04-22
SI2190429T1 (sl) 2016-10-28
JP2016094465A (ja) 2016-05-26
JP2019073560A (ja) 2019-05-16
US9732055B2 (en) 2017-08-15
US20100310503A1 (en) 2010-12-09
CY1117833T1 (el) 2017-05-17
JP5701603B2 (ja) 2015-04-15
CN101854802B (zh) 2014-12-03
EP3067054A1 (en) 2016-09-14
US10851075B2 (en) 2020-12-01
HK1148942A1 (zh) 2011-09-23
JP5688840B2 (ja) 2015-03-25
JP5925849B2 (ja) 2016-05-25
EP3058941A1 (en) 2016-08-24
HUE027657T2 (en) 2016-11-28
CA2736532C (en) 2018-03-20
CN101854937B (zh) 2013-03-27
US20150018410A1 (en) 2015-01-15
US20110112180A1 (en) 2011-05-12
WO2009036059A3 (en) 2009-07-02
DK2200431T3 (en) 2016-08-15
JP6358659B2 (ja) 2018-07-18
CA2736563C (en) 2016-01-26
EP2194987A4 (en) 2011-11-30
ES2583010T3 (es) 2016-09-16
EP3050566A3 (en) 2016-11-30
JP2010539095A (ja) 2010-12-16
US20170197932A1 (en) 2017-07-13
CN104586832A (zh) 2015-05-06
CN104586832B (zh) 2018-02-16
HRP20160949T1 (hr) 2016-10-07
PL2194987T3 (pl) 2017-01-31
US20210024482A1 (en) 2021-01-28
WO2009036101A1 (en) 2009-03-19
PT2200431T (pt) 2016-08-03
EP2194987B1 (en) 2016-05-18
US20120252763A1 (en) 2012-10-04
JP6347795B2 (ja) 2018-06-27
CA2911990C (en) 2018-03-20
WO2009036099A1 (en) 2009-03-19
CN101854930A (zh) 2010-10-06
JP2020117547A (ja) 2020-08-06
CN101854930B (zh) 2016-05-04
EP2200431A1 (en) 2010-06-30
HK1148943A1 (en) 2011-09-23
JP2020143135A (ja) 2020-09-10
CN103288787B (zh) 2016-08-03
EP3067054B1 (en) 2020-12-30
PL2190429T3 (pl) 2016-09-30
PL3067054T3 (pl) 2021-10-04
CA2736564A1 (en) 2009-03-19
EP2190429A4 (en) 2011-12-14
CN105963289A (zh) 2016-09-28
US10377731B2 (en) 2019-08-13
EP2194987A2 (en) 2010-06-16
JP2016065101A (ja) 2016-04-28
DK2190429T3 (en) 2016-05-30
US9745278B2 (en) 2017-08-29
JP2016147906A (ja) 2016-08-18
US20200039948A1 (en) 2020-02-06
US20190263768A1 (en) 2019-08-29
JP5872160B2 (ja) 2016-03-01
US8877803B2 (en) 2014-11-04
CN101854937A (zh) 2010-10-06
JP2018076349A (ja) 2018-05-17
HRP20160430T1 (hr) 2016-05-20
DK3050566T3 (en) 2019-03-11
JP6106149B2 (ja) 2017-03-29
HUE027443T2 (en) 2016-10-28
CN103288787A (zh) 2013-09-11
EP2190429B1 (en) 2016-04-20
US9834532B2 (en) 2017-12-05
EP2200431B1 (en) 2016-07-20
HK1148906A1 (en) 2011-09-23
PT2194987T (pt) 2016-08-05
JP2010539097A (ja) 2010-12-16
CN101854802A (zh) 2010-10-06
ES2584904T3 (es) 2016-09-30
SI2194987T1 (sl) 2016-10-28
EP2200431A4 (en) 2011-12-21
JP6346628B2 (ja) 2018-06-20
JP2014231522A (ja) 2014-12-11
CY1117604T1 (el) 2017-04-26
WO2009036059A2 (en) 2009-03-19
CN105963289B (zh) 2021-02-26
PL2200431T3 (pl) 2017-01-31
JP2015038151A (ja) 2015-02-26
EP3050566B1 (en) 2018-11-28
US20180030022A1 (en) 2018-02-01
EP2190429A1 (en) 2010-06-02
CA2736563A1 (en) 2009-03-19
CA2736532A1 (en) 2009-03-19
DK2194987T3 (en) 2016-08-15
JP5938072B2 (ja) 2016-06-22
US20190135773A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
HRP20160949T1 (hr) Novi sastavi i metode za liječenje karcinoma
IL257681A (en) Methods and compositions for the treatment of cancer
PL3009148T3 (pl) Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
HK1140944A1 (en) Methods and compositions for treating recurrent cancer
IL218987A0 (en) Methods and compositions for treating cancer
HK1159498A1 (en) Methods and compositions for the treatment of cancer
EP2125887A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
HK1137158A1 (en) Formulations for cancer treatment
EP2155249A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2419136A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
HRP20130642T1 (en) Methods and compositions for treating cancers
EP2176406A4 (en) COMPOSITIONS AND METHOD FOR CANCER TREATMENT
EP2391363A4 (en) COMPOSITIONS AND METHOD FOR CANCER TREATMENT
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
IL204945A0 (en) Compositions and methods for inhibiting tumor progression
EP2437738A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2411031A4 (en) Methods and compositions for the treatment of cancer
GB0707556D0 (en) Treatment for cancer
EP2252298A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF LUNG CANCER
PT3067054T (pt) Novas composições e métodos para o tratamento de cancro
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
EP2068629A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
GB0723503D0 (en) Cancer treatment